Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
The purpose of this open label,single arm,phase â…¡ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.
Relapsed or Refractory Peripheral T-cell Lymphoma
DRUG: Chidamide, Lenalidomide
ORR, Overall Response Rate, 4-years
PFS, Progression Free Survival, 4-years|DOR, Duration of Overall Response, 4-years|OS, Overall Survival, 4-years
Histone deacetylase(HDAC) inhibitor has been used in relapsed or refractory peripheral T-cell lymphoma.There are no international studies of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma. Therefore, this study intends to select the oral HDAC inhibitor Chidamide combined with lenalidomide for relapsed or refractory peripheral T-cell lymphoma, and explore its efficacy and safety.